The use of flow cytometry to assess a novel drug efficacy in multiple sclerosis.
The use of flow cytometry to assess a novel drug efficacy in multiple sclerosis.
复制标题
DOI:
10.1007/s11011-014-9634-0
复制
发表时间:
2015-08
影响因子:
3.6
通讯作者:
Vandenbark AA
中科院分区:
文献类型:
--
作者:
Benedek G;Meza-Romero R;Bourdette D;Vandenbark AA
Applying different technologies to monitor disease activity and treatment efficacy are essential in a complex disease such as multiple sclerosis. Combining current assays with flow cytometry could create a powerful tool for such analyses. The cell surface expression level of CD74, the MHC class II invariant chain, is a potential disease biomarker that could be monitored by FACS analysis in order to assess disease progression and the clinical efficacy of partial MHC class II constructs in treating MS. These constructs, which can bind to and down-regulate CD74 cell-surface expression on monocytes and inhibit macrophage migration inhibitory factor (MIF) effects, can reverse clinical and histological signs of EAE. These properties of partial class II constructs are highly compatible with a flow cytometry approach for monitoring CD74 expression as a possible biomarker for disease activity/progression and as a treatment response marker.
登录
查看更多内容
影响因子:
25
作者:
Liu, LiPing;Belkadi, Abdelmadjid;Darnall, Lindsey;Hu, Taofang;Drescher, Caitlin;Cotleur, Anne C.;Padovani-Claudio, Dolly;He, Tao;Choi, Karen;Lane, Thomas E.;Miller, Robert H.;Ransohoff, Richard M.
通讯作者:
Ransohoff, Richard M.
DOI:
10.4049/jimmunol.1303118
发表时间:
2014-05-01
期刊:
Journal of immunology (Baltimore, Md. : 1950)
影响因子:
--
作者:
Meza-Romero R;Benedek G;Yu X;Mooney JL;Dahan R;Duvshani N;Bucala R;Offner H;Reiter Y;Burrows GG;Vandenbark AA
通讯作者:
Vandenbark AA
影响因子:
3.7
作者:
Koch N;Zacharias M;König A;Temme S;Neumann J;Springer S
通讯作者:
Springer S
影响因子:
6
作者:
Kowarik, M. C.;Grummel, V.;Hemmer, B.
通讯作者:
Hemmer, B.
影响因子:
3.6
作者:
Benedek, Gil;Zhu, Wenbin;Offner, Halina
通讯作者:
Offner, Halina